Back to Search
Start Over
Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
- Source :
- Circulation: Cardiovascular Imaging. 7:274-281
- Publication Year :
- 2014
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2014.
-
Abstract
- Background— The incretin hormone, glucagon-like peptide-1, promotes myocardial glucose uptake and may improve myocardial tolerance to ischemia. Endogenous glucagon-like peptide-1 (7–36) is augmented by pharmacological inhibition of dipeptidyl peptidase-4. We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protected against ischemic left ventricular dysfunction during dobutamine stress in patients with type 2 diabetes mellitus and coronary artery disease. Methods and Results— A total of 19 patients with type 2 diabetes mellitus underwent dobutamine stress echocardiography with tissue Doppler imaging on 2 separate occasions: the first (control) while receiving oral hypoglycemic agents, and the second after the addition of sitagliptin (100 mg once daily) for ≈4 weeks. Sitagliptin increased plasma glucagon-like peptide-1 (7–36) levels and, at peak stress, enhanced both global (ejection fraction, 70.5±7.0 versus 65.7±8.0%; P P =0.01) and regional left ventricular function, assessed by peak systolic velocity and strain rate in 12 paired, nonapical segments. This was predominantly because of a cardioprotective effect on ischemic segments (strain rate in ischemic segments, −2.27±0.65 versus −1.98±0.58 s −1 ; P =0.001), whereas no effect was seen in nonischemic segments (−2.19±0.48 versus −2.18±0.54 s −1 ; P =0.87). At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postischemic stunning seen in the control scan. Conclusions— The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning. Clinical Trial Registration— URL: http://www.isrctn.org . Unique identifier ISRCTN61646154.
- Subjects :
- Male
medicine.medical_specialty
Dipeptidyl Peptidase 4
Heart Ventricles
Myocardial Ischemia
Ischemia
Pilot Projects
Coronary Artery Disease
Coronary Angiography
Coronary artery disease
Electrocardiography
Ventricular Dysfunction, Left
Glucagon-Like Peptide 1
Internal medicine
Diabetes mellitus
medicine
Humans
Radiology, Nuclear Medicine and imaging
Dipeptidyl peptidase-4
Aged
Dipeptidyl-Peptidase IV Inhibitors
Ejection fraction
business.industry
Sitagliptin Phosphate
Type 2 Diabetes Mellitus
Stroke Volume
Triazoles
medicine.disease
Glucagon-like peptide-1
Echocardiography, Doppler
Treatment Outcome
Diabetes Mellitus, Type 2
Pyrazines
Sitagliptin
Cardiology
Female
Cardiology and Cardiovascular Medicine
business
Echocardiography, Stress
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 19420080 and 19419651
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Circulation: Cardiovascular Imaging
- Accession number :
- edsair.doi.dedup.....5f39e195893160bf35a0c89477df41b0
- Full Text :
- https://doi.org/10.1161/circimaging.113.000785